All In MedTech

FDA Clearance Tracker · P030047-S049

PRECISE PRO RX Transcarotid Stent System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 4, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 4, 2025

Approved

Time to decision

185 days

Received Oct 1, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P030047-S049
Device name
PRECISE PRO RX Transcarotid Stent System
Applicant location
Miami Lakes, FL
Received
Oct 1, 2024
Decided
Apr 4, 2025
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P030047

Device type

Device class
Class III

Every decision under product code NIM

FDA's approval statement

As written in FDA's record.

The PRECISE® PRO Transcarotid Stent System used in conjunction with the ENROUTE® Transcarotid Neuroprotection System (NPS), is indicated for the treatment of patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet the criteria outlined below.1. Patients with neurological symptoms and >= 50% stenosis of the common or internal carotid artery by ultrasound or angiogram OR patients without neurological symptoms and >= 80% stenosis of the common or internal carotid artery by ultrasound or angiogram, AND2. Patients must have a vessel diameter of 4-9 mm at the target lesion,AND 3. Carotid bifurcation is located at minimum 5cm above the clavicle to allow for placement of the ENROUTE Transcarotid NPS.

Source documents

Other decisions for Cordis US Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.